MindWalk Holdings (HYFT) Cash from Investing Activities (2023 - 2026)
MindWalk Holdings (HYFT) posted quarterly Cash from Investing Activities of $19.8 million for Q2 2026, up 7936.68% year-over-year from $246001.4 in Q2 2025, and up 312.89% quarter-over-quarter from -$9.3 million in Q1 2026.
MindWalk Holdings (HYFT) Cash from Investing Activities (2023 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Cash from Investing Activities for 4 consecutive years, with $19.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Investing Activities rose 7936.68% year-over-year to $19.8 million; the TTM figure through Apr 2026 stood at $10.0 million (up 1851.43% YoY), while the FY2026 annual figure was $9.9 million, up 1822.68% from the prior year.
- Cash from Investing Activities advanced to $19.8 million in Q2 2026 per HYFT's latest filing, from -$9.3 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $19.8 million in Q2 2026 and bottomed at -$9.3 million in Q1 2026.
- Historically, Cash from Investing Activities has averaged $555467.1 across 4 years, with a median of -$179813.6 in 2023.
- On a YoY basis, Cash from Investing Activities climbed as much as 7936.68% in 2026 and fell as far as 11670.84% in 2026.
- MindWalk Holdings' Cash from Investing Activities stood at -$230098.1 in 2023, then surged by 79.31% to -$47598.8 in 2024, then fell by 12.07% to -$53345.0 in 2025, then soared by 37161.25% to $19.8 million in 2026.
- Business Quant data shows HYFT's Cash from Investing Activities at $19.8 million in Q2 2026, -$9.3 million in Q1 2026, and -$53345.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 281.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 19.77 Mn |
| Apr 30, 2026 | 19.77 Mn |
| Jan 31, 2026 | -9.29 Mn |
| Jan 31, 2026 | -9.29 Mn |
| Oct 31, 2025 | -53,345.05 |
| Oct 31, 2025 | -53,345.05 |
| Jul 31, 2025 | -432,304.49 |
| Jul 31, 2025 | -432,304.49 |
| Apr 30, 2025 | -252,279.60 |
| Apr 30, 2025 | -252,279.60 |
| Jan 31, 2025 | -78,895.81 |
| Jan 31, 2025 | -78,895.81 |
| Oct 31, 2024 | -47,598.77 |
| Oct 31, 2024 | -47,598.77 |
| Jul 31, 2024 | -192,072.05 |
| Jul 31, 2024 | -192,072.05 |
| Apr 30, 2024 | -819,385.03 |
| Apr 30, 2024 | -819,385.03 |
| Jan 31, 2024 | 42,164.12 |
| Jan 31, 2024 | 42,164.12 |